RxDoctor Payments Data

Rita Redd, MD

Family Medicine · Thornton, CONPI 1447565064

Payments from drug & device makers

$3,992in general payments, 2019–2025

Across 195 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$788
  • AbbVie$548
  • Amgen$348
  • Lilly USA, LLC$339
  • Boehringer Ingelheim$167
  • plus $770 from 15 others

What the payments were for

  • Food & beverage$3,992100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,992 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$11,706
Medicare patients
58
Services billed
118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$34,591
JardianceEmpagliflozin12$18,746
TrulicityDulaglutide12$14,525
OzempicSemaglutide13$13,150
LinzessLinaclotide23$13,036
EntrestoSacubitril/Valsartan22$7,590
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$3,487
Potassium Chloride139$2,887
LevemirInsulin Detemir22$2,623
Gabapentin163$2,321
Levetiracetam49$1,993
Atorvastatin Calcium133$1,754
Methenamine Hippurate35$1,614
Levothyroxine Sodium125$1,227
Insulin Aspart15$1,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$103$34,591113 claims
Boehringer IngelheimJardiance$167$18,74612 claims
Novo NordiskOzempic, Levemir$788$15,77335 claims
Lilly USA, LLCTrulicity, Humalog$339$15,63827 claims
AbbVieLinzess$548$13,03623 claims
NovartisEntresto$13$7,59022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Thornton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →